JP2020516622A5 - - Google Patents

Download PDF

Info

Publication number
JP2020516622A5
JP2020516622A5 JP2019555180A JP2019555180A JP2020516622A5 JP 2020516622 A5 JP2020516622 A5 JP 2020516622A5 JP 2019555180 A JP2019555180 A JP 2019555180A JP 2019555180 A JP2019555180 A JP 2019555180A JP 2020516622 A5 JP2020516622 A5 JP 2020516622A5
Authority
JP
Japan
Prior art keywords
concentration
pharmaceutically acceptable
acceptable salt
gemkaben
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019555180A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516622A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/028113 external-priority patent/WO2018195163A1/en
Publication of JP2020516622A publication Critical patent/JP2020516622A/ja
Publication of JP2020516622A5 publication Critical patent/JP2020516622A5/ja
Priority to JP2023010250A priority Critical patent/JP2023057082A/ja
Pending legal-status Critical Current

Links

JP2019555180A 2017-04-18 2018-04-18 ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法 Pending JP2020516622A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023010250A JP2023057082A (ja) 2017-04-18 2023-01-26 ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762486728P 2017-04-18 2017-04-18
US201762486822P 2017-04-18 2017-04-18
US62/486,822 2017-04-18
US62/486,728 2017-04-18
US201762569358P 2017-10-06 2017-10-06
US62/569,358 2017-10-06
US201762584576P 2017-11-10 2017-11-10
US62/584,576 2017-11-10
PCT/US2018/028113 WO2018195163A1 (en) 2017-04-18 2018-04-18 Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023010250A Division JP2023057082A (ja) 2017-04-18 2023-01-26 ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法

Publications (2)

Publication Number Publication Date
JP2020516622A JP2020516622A (ja) 2020-06-11
JP2020516622A5 true JP2020516622A5 (cg-RX-API-DMAC7.html) 2021-05-20

Family

ID=63791570

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019555180A Pending JP2020516622A (ja) 2017-04-18 2018-04-18 ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法
JP2023010250A Pending JP2023057082A (ja) 2017-04-18 2023-01-26 ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023010250A Pending JP2023057082A (ja) 2017-04-18 2023-01-26 ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法

Country Status (9)

Country Link
US (4) US20180297929A1 (cg-RX-API-DMAC7.html)
EP (1) EP3612171A4 (cg-RX-API-DMAC7.html)
JP (2) JP2020516622A (cg-RX-API-DMAC7.html)
KR (1) KR20200054910A (cg-RX-API-DMAC7.html)
CN (1) CN110996928A (cg-RX-API-DMAC7.html)
CA (1) CA3059073A1 (cg-RX-API-DMAC7.html)
IL (1) IL269884B2 (cg-RX-API-DMAC7.html)
TW (1) TW201902471A (cg-RX-API-DMAC7.html)
WO (1) WO2018195163A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3218349A2 (en) 2014-11-14 2017-09-20 Gemphire Therapeutics Inc. Processes and intermediates for preparing , -dicarboxylic acid-terminated dialkane ethers
EP3612171A4 (en) 2017-04-18 2020-10-21 Gemphire Therapeutics Inc. GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND PROCEDURES FOR THE USE OF THE SAME
JP2022505033A (ja) * 2018-10-18 2022-01-14 ジェムフィアー セラピューティクス インコーポレイテッド ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法
US20240226049A1 (en) * 2023-01-09 2024-07-11 Esperion Therapeutics, Inc. Methods of treatment using bempedoic acid
WO2024151311A1 (en) * 2023-01-09 2024-07-18 Esperion Therapeutics, Inc. Methods of treatment using bempedoic acid

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2033909A (en) 1934-12-19 1936-03-17 Niacet Chemicals Corp Manufacture of calcium levulinate
CA1197242A (en) * 1983-03-02 1985-11-26 Jean A. Gauthier Pyrimido¬1,2-a|pyrrolo¬2,1-c|¬1, 4|benzodiazepine-3-carboxylic acid derivatives
US4691034A (en) 1986-04-14 1987-09-01 Texaco, Inc. Purification of propylene oxide by treatment with calcium hydroxide in glycerol or sugar water
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
EP1017390B1 (en) 1997-07-31 2007-04-18 Kos Life Sciences, Inc. Coated tablet comprising nicotinic acid or a compound metabolized to nicotinic acid in an extended release form, and a coating containing an hmg-coa reductase inhibitor in an immediate release form
US6861555B2 (en) * 2000-01-25 2005-03-01 Warner-Lambert Company Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
US6459003B1 (en) 1999-04-01 2002-10-01 Esperion Therapeutics, Inc. Ether compounds
NZ519550A (en) 2000-01-25 2003-11-28 Warner Lambert Co Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
CN100376570C (zh) 2000-10-13 2008-03-26 希拉生物化学股份有限公司 改善胞间传输的二氧戊环类似物
HUP0400381A2 (hu) 2001-06-29 2004-09-28 Warner-Lambert Company Llc [R-(R*,R*)]-2-(4fluorfenil)-béta, delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)karbonil]-1H-pirrol-1-heptánsav 2:1 arányú kalciumsójának (atorvasztatin) kristályos formái
US20040192771A1 (en) 2001-10-11 2004-09-30 Dasseux Jean-Louis Henri Ether compounds and compositions for cholesterol management and related uses
DE10211289A1 (de) 2002-03-14 2003-09-25 Basf Ag Kombination von Polyvinylacetat von wasserunlöslichen, säureunlöslichen oder alkaliunlöslichen Polymeren zur Hestellung von Filmüberzügen mit sehr kontrollierter Freisetzung und hoher Stabilität
WO2003088962A1 (en) 2002-04-16 2003-10-30 Merck & Co., Inc. Combination therapy using a ppar alpha/gamma agonist
AU2003227691B2 (en) 2002-05-03 2008-05-15 Hexal Ag Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor
JP2006501238A (ja) 2002-08-22 2006-01-12 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 骨関節炎を治療する方法
WO2004045596A1 (en) 2002-11-15 2004-06-03 Warner-Lambert Company Llc Method of lowering crp and reducing systemic inflammation
ES2645930T3 (es) 2003-01-03 2017-12-11 Supernus Pharmaceuticals, Inc. Utilización de una mezcla de dos o más materiales entéricos para regular la liberación de fármacos a través de una membrana o matriz para terapias sistémicas
WO2005002557A1 (en) 2003-07-03 2005-01-13 Warner-Lambert Company Llc Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof
US20050026979A1 (en) 2003-07-31 2005-02-03 Maha Ghazzi Methods for treating inflammation and inflammation-associated diseases with a statin and ether
US7345190B2 (en) 2003-11-12 2008-03-18 Ssv Therapeutics, Inc. Carnitine conjugates as dual prodrugs and uses thereof
WO2006054308A2 (en) 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
CA2628666A1 (en) 2005-11-21 2007-05-24 Teva Pharmaceutical Industries Ltd. Atorvastatin formulation
CN104825397A (zh) 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US7777071B2 (en) 2006-08-11 2010-08-17 Ssv Therapeutics, Inc. Production of carnitine conjugate intermediates
US20080241240A1 (en) 2006-08-24 2008-10-02 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
WO2008022932A2 (en) 2006-08-25 2008-02-28 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
FI20080353A0 (fi) 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi erittäin korkean lääkepitoisuuden tabletin valmistamiseksi
US9486446B2 (en) 2006-12-28 2016-11-08 Takeda Pharmaceutical Company Limited Orally disintegrating solid preparation
CZ300047B6 (cs) 2007-03-02 2009-01-21 Zentiva, A. S. Farmaceutická kompozice s obsahem úcinné látky atorvastatinu
WO2008124505A2 (en) 2007-04-05 2008-10-16 Ironwood Pharmaceuticals,Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20090036414A1 (en) 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
WO2009024889A2 (en) 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
WO2009048938A1 (en) 2007-10-08 2009-04-16 Keen Ingredients, Inc. Quinoa grain processing and products
BRPI0822026B8 (pt) 2008-01-10 2021-05-25 Evonik Roehm Gmbh preparação farmacêutica ou nutracêutica, comprimido, gelatina ou cápsula de hpmc, e uso de uma ou uma mistura de uma pluralidade de polímeros ou copolímeros
US20090226515A1 (en) 2008-03-04 2009-09-10 Pharma Pass Ii Llc Statin compositions
FR2928925B1 (fr) 2008-03-19 2011-01-07 Centre Nat Rech Scient Complexes de bore ou d'aluminium, et leurs utilisations.
EP2285352A2 (en) 2008-05-13 2011-02-23 Dr. Reddy's Laboratories Ltd. Atorvastatin compositions
RU2010151944A (ru) 2008-05-20 2012-06-27 Серенис Терапьютикс С.А. (Fr) Ниацин и нспвс для комбинированной терапии
RU2404767C1 (ru) 2009-08-11 2010-11-27 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма, обладающая гиполипидемической и гипохолестеринемической активностью, и способ ее получения
AU2011270719B2 (en) 2010-06-24 2015-09-24 Arisaph Pharmaceuticals, Inc. Niacin mimetics, and methods of use thereof
TR201005325A2 (tr) 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Atorvastatin ve aspirin içeren farmasötik formülasyonlar
PL2592081T3 (pl) 2010-07-06 2017-07-31 Ono Pharmaceutical Co., Ltd. Pochodna tetrahydrokarboliny
TW201304823A (zh) 2010-12-27 2013-02-01 Takeda Pharmaceutical 口腔內崩壞錠
ES2608177T3 (es) 2010-12-27 2017-04-06 Gemphire Therapeutics Inc. Gemcabeno y derivados para el tratamiento de la pancreatitis
UA112539C2 (uk) 2011-03-03 2016-09-26 Новартіс Аг Спосіб одержання похідних 2-карбоксамідциклоаміносечовини
CA2835293C (en) * 2011-06-08 2020-08-18 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
RU2491070C2 (ru) 2011-10-11 2013-08-27 Общество с ограниченной ответственностью "Фармамед" Фармацевтическая композиция для профилактики и лечения сердечно-сосудистых заболеваний
EP2787986B1 (en) 2011-12-08 2017-10-18 Syndromex Ltd. Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof
EP2604256B1 (en) 2011-12-14 2016-04-13 Hexal AG Multi layer coatings
JP6295205B2 (ja) * 2012-01-06 2018-03-14 ジェムファイア セラピューティクス インクGemphire Therapeutics Inc. 心血管疾患のリスクを低減する方法
CN104127391B (zh) 2014-08-05 2016-08-24 李宝齐 一种含有阿托伐他汀钙的固体药物组合物
EP3218349A2 (en) * 2014-11-14 2017-09-20 Gemphire Therapeutics Inc. Processes and intermediates for preparing , -dicarboxylic acid-terminated dialkane ethers
MX2018005096A (es) * 2015-11-06 2018-08-15 Gemphire Therapeutics Inc Combinaciones de gemcabeno para el tratamiento de enfermedad cardiovascular.
CN105434391A (zh) 2016-01-18 2016-03-30 上海蓝心医药科技有限公司 阿托伐他汀钙肠溶片及其制备方法和应用
EP3612171A4 (en) 2017-04-18 2020-10-21 Gemphire Therapeutics Inc. GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND PROCEDURES FOR THE USE OF THE SAME
WO2018209257A1 (en) 2017-05-11 2018-11-15 Gemphire Therapeutics Inc. Gemcabene compositions and methods of use thereof

Similar Documents

Publication Publication Date Title
Zhang et al. Pathological impacts of chronic hypoxia on Alzheimer’s disease
Flume et al. State of progress in treating cystic fibrosis respiratory disease
Raij et al. Podocyte injury: the role of proteinuria, urinary plasminogen, and oxidative stress
Peng et al. Salvia miltiorrhiza restrains reactive oxygen species-associated pulmonary fibrosis via targeting Nrf2-Nox4 redox balance
Liu et al. Rivaroxaban suppresses the progression of ischemic cardiomyopathy in a murine model of diet-induced myocardial infarction
Shaw The next wave of influenza drugs
Yin et al. Role of P2X7R in the development and progression of pulmonary hypertension
Xiang et al. Neotuberostemonine attenuates bleomycin-induced pulmonary fibrosis by suppressing the recruitment and activation of macrophages
CN110025608A (zh) 降低心血管疾病风险的方法
Colliou et al. Oxalate nephropathy following vitamin C intake within intensive care unit
WO2021191108A1 (en) Treatment or prevention of acute organ damage induced by viral infection with a nk1 inhibitor and/or a gabapentinoid
JP2023085268A (ja) 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Bclファミリーアンタゴニストであるアシルスルホンアミド
Florentin et al. Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation
US20220184031A1 (en) Dual antagonist of pgd2/dpr2 and thromboxane a2/tpr receptors and use for treatment of maladaptive immune response or thrombotic diathesis
Wang et al. Synergistic effects of notoginsenoside R1 and saikosaponin B2 in atherosclerosis: a novel approach targeting PI3K/AKT/mTOR pathway and macrophage autophagy
Villaschi et al. Diuretic combination therapy in acute heart failure: an updated review
Wang et al. TRAIL inhibition by soluble death receptor 5 protects against acute myocardial infarction in rats
JP2020531539A5 (cg-RX-API-DMAC7.html)
Atwa et al. Protective effects of the third generation vasodilatory βeta-blocker nebivolol against D-galactosamine-induced hepatorenal syndrome in rats
Waters What do the statin trials tell us?
Yagi et al. Effects of statins on cardiorenal syndrome
CN107648210A (zh) 用于治疗胰腺炎的吉卡宾和衍生物
CN114569608A (zh) Aerd/哮喘中的血栓烷受体拮抗剂
CHAPMAN Comorbidities in Gout
Štvrtinová et al. Vasculitis of the coronary arteries and atherosclerosis: random coincidence or causative relationship?